LONG BEACH, Calif. / Aug 20, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that its Board of Directors has entered into a contract amendment with President and Chief Executive Officer, Joe Zubretsky, designed to secure Mr. Zubretsky’s tenure through at least the end of 2027. Zubretsky, 67, joined Molina as President and Chief Executive Officer in November of 2017.
“Under Joe’s leadership we have the right strategy, great execution, and have created significant value for shareholders,” said Dale Wolf, Molina’s Chairman of the Board. “We are delighted that Joe will be at the helm for the foreseeable future to continue to do so.”
Under this contract amendment, Zubretsky was awarded a special one-time stock grant that will vest at the end of 2027 contingent upon the achievement of certain financial targets. His annual compensation remains unchanged.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.
| Last Trade: | US$166.90 |
| Daily Change: | 6.38 3.97 |
| Daily Volume: | 1,512,713 |
| Market Cap: | US$8.580B |
November 14, 2025 October 22, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
